Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective

norepinephrine reuptake inhibitor A norepinephrine reuptake inhibitor (NRI, NERI) or noradrenaline reuptake inhibitor or adrenergic reuptake inhibitor (ARI), is a type of drug that acts as a reuptake inhibitor for the neurotransmitters norepinephrine (noradrenaline) and epin ...

which was under development by

Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...

for the treatment of

neuropathic pain Neuropathic pain is pain caused by damage or disease affecting the somatosensory system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous ...

and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the (''S'',''S'')-(+)- enantiomer of

reboxetine Reboxetine, sold under the brand name Edronax among others, is a drug of the norepinephrine reuptake inhibitor (NRI) class, marketed as an antidepressant by Pfizer for use in the treatment of major depression, although it has also been used of ...

and is even more selective as a norepinephrine reuptake inhibitor in comparison. However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.

References

Enantiopure drugs Morpholines Norepinephrine reuptake inhibitors Pfizer brands Phenol ethers {{Analgesic-stub